Interchangeability and Comparative Effectiveness between Micronized and Non-micronized Products of Glibenclamide Tablets

Authors

  • Amjad M Idries Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Khartoum
  • Mohammed E Ahmed Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Khartoum
  • Mahmoud E Mudawi Department of Chemistry, Faculty of Sciences, University of Khartoum
  • Kamal E Ibrahim Department of Pharmacology, Faculty of Pharmacy, Omdurman Islamic University

DOI:

https://doi.org/10.52981/sjms.v7i3.831

Keywords:

sulfonylurea, Blood glucose, hypoglycemia

Abstract

Background: During the last few years there was wide debate about the interchangeability and effectiveness between circulated products containing Glibenclamide in the market.
Objectives: This study aimed to compare the effectiveness of this product “non-micronized” to the originator’s product of Glibenclamide tablets “of micronized” sulfonylurea.
Methods: 12 volunteers received a dose of 5mg of Glibenclamide (from test and standard products) under fasting conditions in two separate sessions using randomized crossover design. Blood glucose level for the volunteers was monitored to avoid the development of hypoglycemia. Plasma samples were collected over 24 hours and analyzed using HPLC.
Results: The maximum concentration Cmax for the test and reference products were 2.508 ± 0.104 and 3.526 ± 0.118 (ìg/ml) respectively and the area under the curve AUC0-[ were 3.511 ± 0.153 4.572 ± 0.202 (ìg.h/ml) for these products respectively, with a difference of about 24% between the test and reference products in its AUC.
Conclusions: The results indicate that the test product is not bioequivalent to reference product. The difference in formulation between micronized product and non-micronized product of Glibenclamide tablets has impact on clinical outcomes.

References

1. WHO. (1998). Marketing Authorization of
Pharmaceutical Products with SpecialReference to
Multisource (Generic) products. Geneva: World
Health Organization.
2. Harris, Daniel C. Quantitative Chemical Analysis, 6th ed. 2003.New York: W.H. Freeman.
3. NMPB. (2010). Sudan - National Medicines and Poisons Baord.
4. Idries A., Kamal I. Unpublish report – Quality Monitoring Survey 2009-2010
5. WHO. (2003). WHO Expert Committee on Specifications for Pharmaceutical Preparations. Geneva: World Health Organization.
6. FDA. (2000). Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Food and Drug Administration.
7. Buice, R. G. (2005). Bioequivalence and In VitroIn Vivo Correlations: Study Design & Data Interpretation based on the Biopharmaceutic Classification System.
8. WMA. (2008). Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects. World Medical Association.
9. Katzung, B. G. (2001). Basic & Clinical Pharmacology. Lange Basic Science.
10. Meyer, H., Muller, F., Luus, H., & Eckert, H. (1989). Bio-availability of three formulations of glibenclamide. SAMJ , 76.
11. Rajendran S D, Philip BK, Gopinath R et al.HPLC method for the estimation of Glibenclamide in human serum. Indian J Pharm Sci 2005; 25: 12-19.
12. Watson, D. G. (2005). Pharmaceutical Analysis: A Textbook for Pharmacy Students and Pharmaceutical Chemists (2 ed.). Paperback, Churchill Livingstone.
13. FMOH. (2008). Health Statistics Report 2007. Federal Ministry of Health.
14. Meredith, P. Bioequivalence and other unresolved issues in generic drug substitution. Clinical Therapeutics 2003;25 (11): 2875-2890.
15. Tschabitscher, D., Platzer P, Baumgärtel C et al. Generic drugs: quality, efficacy, safety and interchangeability. Wien Klin Wochenschr , 2008;3-4 (120): 63-9.
16. CoppackS. W., LantA. F., Mcintosh C. S et al. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus, Br. J. clin. Pharmac. 1990; 29: 673-684

Downloads

Published

2021-08-08

Issue

Section

Original Articles